Literature DB >> 19011957

The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.

Karin Tunblad1, Lars Lindbom, Lynn McFadyen, E Niclas Jonsson, Scott Marshall, Mats O Karlsson.   

Abstract

To characterise the pharmacokinetics of dofetilide in patients and to identify clinically relevant parameter-covariate relationships. To investigate three different modelling strategies in covariate model building using dofetilide as an example: (1) using statistical criteria only or in combination with clinical irrelevance criteria for covariate selection, (2) applying covariate effects on total clearance or separately on non-renal and renal clearances and (3) using separate data sets for covariate selection and parameter estimation. Pooled concentration-time data (1,445 patients, 10,133 observations) from phase III clinical trials was used. A population pharmacokinetic model was developed using NONMEM. Stepwise covariate model building was applied to identify important covariates using the strategies described above. Inclusion and exclusion of covariates using clinical irrelevance was based on reduction in interindividual variability and changes in parameters at the extremes of the covariate distribution. Parametric separation of the elimination pathways was accomplished using creatinine clearance as an indicator of renal function. The pooled data was split in three parts which were used for covariate selection, parameter estimation and evaluation of predictive performance. Parameter estimations were done using the first-order (FO) and the first-order conditional estimation (FOCE) methods. A one-compartment model with first order absorption adequately described the data. Using clinical irrelevance criteria resulted in models containing less parameter-covariate relationships with a minor loss in predictive power. A larger number of covariates were found significant when the elimination was divided into a renal part and a non-renal part, but no gain in predictive power could be seen with this data set. The FO and FOCE estimation methods gave almost identical final covariate model structures with similar predictive performance. Clinical irrelevance criteria may be valuable for practical reasons since stricter inclusion/exclusion criteria shortens the run times of the covariate model building procedure and because only the covariates important for the predictive performance are included in the model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011957     DOI: 10.1007/s10928-008-9099-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  25 in total

1.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

2.  Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.

Authors:  M J Suttorp; P E Polak; A van 't Hof; H S Rasmussen; P H Dunselman; J H Kingma
Journal:  Am J Cardiol       Date:  1992-02-01       Impact factor: 2.778

3.  Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay.

Authors:  D K Walker; G W Aherne; J E Arrowsmith; P E Cross; B Kaye; D A Smith; D A Stopher; W Wild
Journal:  J Pharm Biomed Anal       Date:  1991       Impact factor: 3.935

4.  Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug.

Authors:  M Sedgwick; H S Rasmussen; D Walker; S M Cobbe
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

5.  UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.

Authors:  M Gwilt; J E Arrowsmith; K J Blackburn; R A Burges; P E Cross; H W Dalrymple; A J Higgins
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

6.  Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans.

Authors:  T C Tham; B A MacLennan; M T Burke; D W Harron
Journal:  J Cardiovasc Pharmacol       Date:  1993-03       Impact factor: 3.105

7.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

8.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.

Authors:  R H Falk; A Pollak; S N Singh; T Friedrich
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

9.  Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.

Authors:  D K Walker; C T Alabaster; G S Congrave; M B Hargreaves; R Hyland; B C Jones; L J Reed; D A Smith
Journal:  Drug Metab Dispos       Date:  1996-04       Impact factor: 3.922

10.  Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.

Authors:  D A Smith; H S Rasmussen; D A Stopher; D K Walker
Journal:  Xenobiotica       Date:  1992-06       Impact factor: 1.908

View more
  13 in total

Review 1.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

2.  A fast method for testing covariates in population PK/PD Models.

Authors:  Akash Khandelwal; Kajsa Harling; E Niclas Jonsson; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2011-07-02       Impact factor: 4.009

3.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.

Authors:  Junjie Ding; Yi Wang; Weiwei Lin; Changlian Wang; Limei Zhao; Xingang Li; Zhigang Zhao; Liyan Miao; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

5.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

7.  Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.

Authors:  Shansen Xu; Limin Liu; Yanan Chen; Mei Liu; Tong Lu; Huanxin Wang; Shihao Liu; Mingming Zhao; Limei Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-01-16       Impact factor: 2.953

8.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

9.  Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study.

Authors:  Muhammad Erfan Uddin; Xinxin Sun; Kevin M Huang; Shuiying Hu; Cynthia A Carnes; Alex Sparreboom; Qiang Fu
Journal:  J Pharm Biomed Anal       Date:  2019-04-19       Impact factor: 3.935

10.  Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage.

Authors:  Åsa M Johansson; Mats O Karlsson
Journal:  AAPS J       Date:  2013-07-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.